Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:chemical_formula |
C6484 H10080 N1716 O2016 S44
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:developed_by |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:effective_date |
FDA approved
|
| https://www.w3.org/2000/01/rdf-schema#label |
ALXN1210
|
| gptkbp:indication |
gptkb:Atypical_Hemolytic_Uremic_Syndrome
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:targets |
complement component C5
|
| gptkbp:used_for |
treatment of paroxysmal nocturnal hemoglobinuria
|
| gptkbp:weight |
146,000 Da
|
| gptkbp:bfsParent |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:bfsLayer |
5
|